Michael Rich

Also affiliated with Partners In Health, Harvard Global Health Institute

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial”.

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(25)00194-8

N/A

0.781DataRank · unranked

26 citations

Uzma Khan, Gustavo E. Velásquez, Maëlenn Gouillou, Muhammad Hammad Ali, Samreen Amjad +95 more

Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan

Clinical Infectious Diseases(2024)10.1093/cid/ciae305

N/A

0.542DataRank · unranked

8 citations

Molly F. Franke, Letizia Trevisi, Gulzhanat Bekbolatova, Julia Shalimova, Gafurzhan Eshmetov +13 more

Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up

Clinical Infectious Diseases(2023)10.1093/cid/ciad589

N/A

0DataRank · unranked

7 citations

Carole D. Mitnick, Uzma Khan, Catherine Hewison, Mathieu Bastard, David Holtzman +21 more

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

PLOS Global Public Health(2023)10.1371/journal.pgph.0000818

N/A

0DataRank · unranked

5 citations

Sara Lodi, C. Robert Horsburgh, Carole D. Mitnick, Mathieu Bastard, Helena Huerga +26 more

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

medRxiv(2024)10.1101/2024.01.18.24301453

N/A

0DataRank · unranked

0 citations

Miguel A. Hernán, Letizia Trevisi, Sara Sauer, Carole D. Mitnick, Catherine Hewison +24 more

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.22.0613

N/A

0DataRank · unranked

14 citations

Uzma Khan, Chao Zeng, Allison LaHood, Molly F. Franke, S Atwood +26 more

Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: A multicountry cohort study

medRxiv(2025)10.1101/2025.08.20.25334077

N/A

0DataRank · unranked

0 citations

Allison LaHood, Helen R. Stagg, Carole D. Mitnick, Letizia Trevisi, Cathy Hewison +18 more

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

The International Journal of Tuberculosis and Lung Disease(2023)10.5588/ijtld.22.0324

N/A

0DataRank · unranked

7 citations

Carole D. Mitnick, Catherine Hewison, Mathieu Bastard, Palwasha Khan, Kwonjune J. Seung +22 more